PTC Therapeutics director discloses stock holdings
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer reports beneficial ownership of 46,526 shares of common stock held directly, including multiple unvested RSU awards.
Rhea-AI Filing Summary
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer reports beneficial ownership of 46,526 shares of common stock held directly, including multiple unvested RSU awards. She also holds several stock options over common stock, three of which are currently exercisable for 14,000, 33,250 and 17,875 shares at exercise prices of $51.96, $66.49 and $38.10, respectively, with additional option grants vesting over four years on specified schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Sollie-Zetlmayer Hege Elisabeth
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F6 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 153,875 contracts (Direct);
Common Stock — 46,526 shares (Direct)
Footnotes (6)
- F1. Includes (1) 2,250 unvested Restricted Stock Units ("RSUs") from an award of 9,000 RSUs granted on January 5, 2023, which vests in four equal installments over four years, commencing on January 5, 2024; (2) 5,000 unvested RSUs from an award of 10,000 RSUs granted on February 15, 2024, which vests in four equal installments over four years, commencing on February 15, 2025; (3) 7,500 unvested RSUs from an award of 10,000 RSUs granted on January 3, 2025, which vests in four equal installments over four years, commencing on January 3, 2026; and (4) 11,000 unvested RSUs from an award of 11,000 RSUs granted on January 2, 2026, which vests in four equal installments over four years, commencing on January 2, 2027.
- F2. Currently exercisable.
- F3. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
- F4. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
- F5. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
- F6. This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
Key Figures
Direct common shares: 46,526 shares
Option at $51.96: 14,000 shares
Option at $66.49: 33,250 shares
+4 more
7 metrics
Direct common shares
46,526 shares
Common Stock held directly following the reported holdings
Option at $51.96
14,000 shares
Stock option currently exercisable; expiration 2030-10-22
Option at $66.49
33,250 shares
Stock option currently exercisable; expiration 2031-01-05
Option at $38.10
17,875 shares
Stock option currently exercisable; expiration 2032-01-06
Option at $39.42
11,250 shares
Stock option grant vesting over four years; expiration 2033-01-04
Unvested RSUs from 2023 grant
2,250 RSUs
From 9,000-RSU award granted January 5, 2023
Unvested RSUs from 2026 grant
11,000 RSUs
From 11,000-RSU award granted January 2, 2026
Key Terms
Restricted Stock Units (RSUs), Stock Option (Right to Buy), currently exercisable, vests over four years
4 terms
Restricted Stock Units (RSUs) financial
"Includes 2,250 unvested Restricted Stock Units (RSUs) from an award of 9,000 RSUs granted on January 5, 2023"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Stock Option (Right to Buy) financial
"Security title shown as Stock Option (Right to Buy) with underlying Common Stock shares"
currently exercisable financial
"Footnote states that certain stock options are currently exercisable"
vests over four years financial
"Each listed option grant vests over four years with specified initial and quarterly vesting dates"
A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity stake does director Hege Elisabeth Sollie-Zetlmayer report in PTC Therapeutics (PTCT)?
She reports beneficial ownership of 46,526 shares of PTC Therapeutics common stock held directly. This total includes vested shares and multiple unvested RSU awards described in the footnotes, reflecting her current equity position as a member of the company’s board.
How many unvested RSUs are included in the PTCT director’s holdings and when were they granted?
Her direct holdings include unvested RSUs from four grants: 2,250 from a 9,000-RSU grant on January 5, 2023; 5,000 from a 10,000-RSU grant on February 15, 2024; 7,500 from a 10,000-RSU grant on January 3, 2025; and 11,000 from an 11,000-RSU grant on January 2, 2026.
Does this PTC Therapeutics (PTCT) Form 3 show any insider stock purchases or sales?
No. The Form 3 lists holdings only, including common stock, stock options and RSUs. The transaction summary shows zero buy and sell transactions, indicating that the filing records existing positions rather than reporting new purchases or sales of PTCT shares.
Are any of the director’s PTCT stock options currently exercisable?
Yes. Footnotes indicate that certain options are currently exercisable, including positions over 14,000, 33,250 and 17,875 underlying shares at exercise prices of $51.96, $66.49 and $38.10, respectively, with later grants vesting over four years on quarterly schedules.
AI-generated analysis. How Rhea-AI works. Not financial advice.
